BioMarin to acquire LEAD Therapeutics

BioMarin to acquire LEAD Therapeutics

 

NOVATO, Calif., Feb 04, 2010 /PRNewswire via COMTEX/ — BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that it has entered into a stock purchase agreement to acquire LEAD Therapeutics, Inc. (LEAD), a small private drug discovery and early stage development company with key compound LT-673, an orally available poly (ADP-ribose) polymerase (PARP) inhibitor for the treatment of patients with rare, genetically defined cancers.

LEAD Therapeutics presents new antibiotic with potent activity against drug resistant bacteria at the 49th ICAAC

 
SAN BRUNO, Calif. & SHANGHAI–(BUSINESS WIRE)–LEAD Therapeutics, a privately held drug discovery company, announced the discovery of a novel antibiotic with potent activity against many of the most common antibiotic resistant bacteria. LEAD will present the new glycopeptide antibiotic, LT-29, for the first time at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). LT-29 is in preclinical development to treat serious infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria.